Gene polymorphisms affect postoperative imatinib plasma levels and edema in adults with gastrointestinal stromal tumor

References

• 1. Blay JY, Kang YK, Nishida T, von Mehren M. Gastrointestinal stromal tumours. Nat. Rev. Dis. Primers. 7(1), 22 (2021).
  MedlineGoogle Scholar
• 2. Inayat F, Saif MW. New drug and possible new toxicity – squamous cell carcinoma following imatinib in patients with gastrointestinal stromal tumors. Anticancer Res. 36(11), 6201–6204 (2016).
  MedlineGoogle Scholar
• 3. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet 382(9896), 973–983 (2013).
  Medline CASGoogle Scholar
• 4. Casali PG, Le Cesne A, Poveda Velasco A et al. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J. Clin. Oncol. 33(36), 4276–4283 (2015).
  Medline CASGoogle Scholar
• 5. Verboom MC, Kloth JSL, Swen JJ et al. Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. Pharmacogenomics J. 19(5), 473–479 (2019).
  Medline CASGoogle Scholar
• 6. Xia Y, Chen S, Luo M et al. Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors. Cancer 126(Suppl. 9), 2054–2061 (2020).
  Medline CASGoogle Scholar
• 7. Menon-Andersen D, Mondick JT, Jayaraman B et al. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother. Pharmacol. 63(2), 229–238 (2009).
  Medline CASGoogle Scholar
• 8. Westerdijk K, Desar IME, Steeghs N et al. Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br. J. Clin. Pharmacol. 86(2), 258–273 (2020).
  MedlineGoogle Scholar
• 9. Evans WE, McLeod HL. Pharmacogenomics – drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538–549 (2003).
  Medline CASGoogle Scholar
• 10. Zhang Q, Xu J, Qian Y et al. Association of imatinib plasma concentration and single-nucleotide polymorphisms with adverse drug reactions in patients with gastrointestinal stromal tumors. Mol. Cancer Ther. 17(12), 2780–2787 (2018).
  Medline CASGoogle Scholar
• 11. Lander ES. The new genomics: global views of biology. Science 274(5287), 536–539 (1996).
  Medline CASGoogle Scholar
• 12. Bhatti MT, Salama AKS. Neuro-ophthalmic side effects of molecularly targeted cancer drugs. Eye 32(2), 287–301 (2018).
  Medline CASGoogle Scholar
• 13. DeMatteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669), 1097–1104 (2009).
  Medline CASGoogle Scholar
• 14. Liu J, Chen Z, Chen H et al. Genetic polymorphisms contribute to the individual variations of imatinib mesylate plasma levels and adverse reactions in Chinese GIST patients. Int. J. Mol. Sci. 18(3), 603 (2017).
  MedlineGoogle Scholar
• 15. Sobel RK, Carter KD, Allen RC. Periorbital edema: a puzzle no more? Curr. Opin. Ophthalmol. 23(5), 405–414 (2012).
  MedlineGoogle Scholar
• 16. Qiu HB, Zhuang W, Wu T et al. Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. Pharmacogenomics J. 18(3), 460–466 (2018).
  Medline CASGoogle Scholar
• 17. Li J, Wang M, Zhang B et al. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors. World J. Gastroenterol. 24(46), 5189–5202 (2018).
  Medline CASGoogle Scholar
• 18. Stoll DR, Li X, Wang X, Carr PW, Porter SE, Rutan SC. Fast, comprehensive two-dimensional liquid chromatography. J. Chromatogr. A 1168(1–2), 3–43 (2007).
  Medline CASGoogle Scholar
• 19. Xu Q, Xu L, Zhang M et al. Influence of NFATC1 Polymorphisms on the Incidence of Chronic Rejection in Renal Transplant Patients. Chinese Journal of Pharmacoepidemiology. 29(06), 413–420 (2020).
  CASGoogle Scholar
• 20. Van Glabbeke M, Verweij J, Casali PG et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur. J. Cancer 42(14), 2277–2285 (2006).
  Medline CASGoogle Scholar
• 21. Liu X, Qiu H, Zhang P et al. Prognostic factors of primary gastrointestinal stromal tumors: a cohort study based on high-volume centers. Chin. J. Cancer Res. 30(1), 61–71 (2018).
  Medline CASGoogle Scholar
• 22. Xu H, Liu Q. Individualized management of blood concentration in patients with gastrointestinal stromal tumors. Onco Targets Ther. 13, 13345–13355 (2020).
  Medline CASGoogle Scholar
• 23. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum. Pathol. 39(10), 1411–1419 (2008).
  MedlineGoogle Scholar
• 24. Heuchel R, Berg A, Tallquist M et al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling. Proc. Natl Acad. Sci. USA 96(20), 11410–11415 (1999).
  Medline CASGoogle Scholar
• 25. Esmaeli B, Prieto VG, Butler CE et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 95(4), 881–887 (2002).
  MedlineGoogle Scholar
• 26. Pietras K, Ostman A, Sjoquist M et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61(7), 2929–2934 (2001).
  Medline CASGoogle Scholar
• 27. Postel-Vinay S, Collette L, Paoletti X et al. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. Eur. J. Cancer 50(12), 2040–2049 (2014).
  MedlineGoogle Scholar
• 28. Wozniak A, Rutkowski P, Piskorz A et al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann. Oncol. 23(2), 353–360 (2012).
  Medline CASGoogle Scholar
• 29. Ushimaru Y, Takahashi T, Nakajima K et al. Real-world data on the efficacy and safety of adjuvant chemotherapy in Japanese patients with a high-risk of gastrointestinal stromal tumor recurrence. Int. J. Clin. Oncol. 27(5), 921–929 (2022).
  Medline CASGoogle Scholar
• 30. Patrikidou A, Chabaud S, Ray-Coquard I et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann. Oncol. 24(4), 1087–1093 (2013).
  Medline CASGoogle Scholar
• 31. Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat. Rev. 37(1), 75–88 (2011).
  Medline CASGoogle Scholar
• 32. Chin-Yee B, Xenocostas A. Successful treatment of imatinib-induced periorbital edema with a sodium-glucose cotransporter-2 inhibitor. Ann. Hematol. 101(6), 1373–1374 (2022).
  Medline CASGoogle Scholar
• 33. Koo DH, Ryu MH, Ryoo BY et al. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. Cancer Chemother. Pharmacol. 75(1), 173–182 (2015).
  Medline CASGoogle Scholar
• 34. Dulucq S, Krajinovic M. The pharmacogenetics of imanitib. Genome. Med. 2(11), 85 (2010).
  MedlineGoogle Scholar
• 35. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science. 315(5811), 525–528 (2007).
  Medline CASGoogle Scholar
• 36. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2(5), 561–566 (1996).
  Medline CASGoogle Scholar
• 37. Liu J, Xi H, Jiang Y et al. Association of CYP450 single nucleotide polymorphisms with the efficacy of epidural ropivacaine during mastectomy. Acta Anaesth. Scand. 59(5), 640–647 (2015).
  Medline CASGoogle Scholar